Endologix Appoints Andrew Davis as Chief Commercial Officer

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held global medical device company specializing in innovative therapies for vascular disease, is pleased to announce the appointment of Andrew Davis as its new Chief Commercial Officer, effective immediately.

Andrew joins Endologix with an extensive background in commercial leadership, having most recently served as the Chief Commercial Officer at Silk Road Medical where he successfully spearheaded the go-to-market strategy for a groundbreaking therapy to treat carotid artery disease (TCAR). With expertise in revenue optimization, customer engagement, and market expansion, he is poised to play a key role in advancing the company’s strategic objectives.

Andy brings to Endologix over 25 years of experience in the medical device field, as well as expertise in launching innovative, minimally invasive therapies that increase patient access and solve unmet clinical needs in cardiovascular diseases. Prior to joining Silk Road Medical, Andy was the Vice President of Sales and Marketing at 3M’s Advanced Wound Therapy Group. Prior to 3M, he spent 15 years at Medtronic and held various Vice President of Sales positions in Cardiac and Vascular Therapies to include TAVR, Endovascular EVAR/TEVAR, Peripheral Vascular, and Spine/Biologics. Andy received a B.S. in Political Science from Florida State University.

“We are thrilled to welcome Andrew Davis to our leadership team,” said Dr. John Liddicoat, President and Chief Executive Officer at Endologix. “He brings a strong track record of success and innovation in the commercial space, and we are confident that his leadership will help us accelerate our growth and strengthen our market position.”

In this role, Andrew will focus on aligning commercial operations with the company’s long-term vision, enhancing customer relationships, and driving new business opportunities. His leadership will be instrumental in executing Endologix’s ambitious growth plans.

“I am excited to join Endologix at such a pivotal moment,” said Andrew Davis. “I look forward to working with the talented team here to expand our market presence, drive revenue growth, and deliver exceptional value to our customers.”

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com.